Evoke Pharma's 15min chart shows KDJ Death Cross, Bearish Marubozu.

Evoke Pharma's 15-minute chart indicates a significant bearish trend, as the KDJ Death Cross and Bearish Marubozu at 09/03/2025 13:00 suggest a shift in momentum towards the downside. This is reinforced by the dominance of sellers in the market, which is likely to result in further price decreases. Therefore, the bearish momentum is expected to continue.

Evoke Pharma, a specialty pharmaceutical company focused on gastrointestinal (GI) diseases, has recently faced a significant downturn in its stock price. According to the company's 15-minute chart, a KDJ Death Cross and Bearish Marubozu were triggered on August 28th at 4:00 PM, indicating a shift in momentum towards a downward trend [1]. This technical analysis suggests that sellers currently dominate the market, and bearish momentum is likely to persist.

Despite the bearish trend, Evoke Pharma has been making strategic moves to expand access to its flagship treatment, GIMOTI (metoclopramide) nasal spray. The company has entered into agreements with Omnicell and Brentwood Pharmacy, managed by Eversana, a leading provider of global commercial services to the life sciences industry. These partnerships aim to enhance patient access to GIMOTI by aligning with trusted specialty pharmacies that GI physicians use daily [1].

Omnicell, a leader in medication management and fulfillment, will manage the collection of specialty pharmacies that specialize in GI products and are affiliated with large gastrointestinal physician organizations. This partnership is expected to almost double the number of specialty pharmacies available to access GIMOTI, thereby significantly improving patient access to the only FDA-approved nasal spray for adults with acute and recurrent diabetic gastroparesis [1].

In a separate agreement, Evoke has accessed Brentwood Pharmacy via a partnership agreement facilitated by Eversana. Brentwood Pharmacy is the specialty pharmacy affiliated with OneGI, a large gastroenterology network located in Tennessee, Kentucky, Ohio, Mississippi, and surrounding states. This expansion further enables rapid delivery of GIMOTI and expands access to additional insurance plans for patients [1].

GIMOTI is indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. The gastric delay caused by gastroparesis can compromise the absorption of orally administered medications, making GIMOTI a crucial treatment option. Prior to FDA approval to commercially market GIMOTI, metoclopramide was only available in oral and injectable formulations and remains the only drug currently approved in the United States to treat gastroparesis [1].

Evoke Pharma's commitment to improving patient access through strategic partnerships and innovative commercial strategies is evident in these recent developments. However, the bearish trend in the stock market, indicated by the KDJ Death Cross and Bearish Marubozu, suggests that investors may face challenges in the near future.

References:
[1] Evoke Pharma and Eversana Expand GIMOTI Access to Gastro Health and Other Large GI Practices. Retrieved from [https://www.marketscreener.com/news/evoke-pharma-and-eversana-expand-gimoti-access-to-gastro-health-and-other-large-gi-practices-through-ce7c50dedf81f722](https://www.marketscreener.com/news/evoke-pharma-and-eversana-expand-gimoti-access-to-gastro-health-and-other-large-gi-practices-through-ce7c50dedf81f722)